Quantcast

Reportlinker Adds Autoimmune Disease Therapeutics Report

September 8, 2009

NEW YORK, Sept. 8 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue.

Autoimmune Disease Therapeutics

http://www.reportlinker.com/p0131243/Autoimmune-Disease-Therapeutics.html

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Billion by the following therapeutic class – Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics only), and Others. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 115 companies including many key and niche players worldwide such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co., Ltd., Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, Novartis AG, Sanofi-aventis SA , Schering-Plough Corporation, Shire Pharmaceuticals Group plc, Teva Pharmaceuticals Industries Limited, and UCB Pharma. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definition and Scope of Study I-3

Rheumatoid Arthritis I-3

Multiple Sclerosis I-4

Psoriasis I-4

Crohn’s disease I-4

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW & OUTLOOK II-1

Autoimmune Disease Therapeutics Market Continues to Flourish II-1

Pharmaceutical Industry Hit by Economic Downturn II-1

Credit Crunch to Affect Biological Drug Pipeline II-1

Biotech Bankruptcies Rife in the Current Economic Downturn II-2

Economic Downturn Takes Toll on R&D II-2

Global Market Estimates and Forecasts II-2

Analysis by Region II-2

Analysis by Segment II-3

2. MARKET DYNAMICS AND TRENDS II-4

Biologics Continue to Gain Market Share II-4

New Products to Drive Market Growth II-4

Biogenerics to Expand Adoption of Biological Drugs II-4

New Indications to Fuel Market Growth II-5

Superior Outcomes to Enhance Adoption of Biologics II-5

Efficacy and Convenience – Key Factors Driving Physician’s

Decision II-5

3. DISEASE OVERVIEW II-6

Immunity and Immune System II-6

Autoimmune Diseases II-6

Women- Highly Susceptible to Autoimmune Diseases II-6

Table 1: Percentage Breakdown of Incidence of Autoimmune

Diseases in Men and Women (includes corresponding

Graph/Chart) II-7

Complexity in Manifestations Renders Difficulty in

Understanding the Conditions II-7

Etiology of Autoimmune Diseases II-8

Genetic Predisposition II-8

Environmental Factors II-9

Autoimmune Diseases – A Social and Health Burden II-9

Regulatory Glitches and High Costs Hinder Biogenerics II-9

Types of Autoimmune Diseases II-10

Incidence and Prevalence II-11

Diagnosis and Treatment of Autoimmune Diseases II-11

Overview on Select Biologic Drugs II-11

Remicade II-11

Humira II-12

Rituxan(R) (rituximab) II-12

Cimzia II-13

Cimzia to Face Stiff Competition in Rheumatoid Arthritis Market II-13

Psoriasis – A Promising Market for Cimzia II-14

Actemra II-14

Enbrel II-14

4. OVERVIEW OF SELECT AUTOIMMUNE DISEASES II-15

Rheumatoid Arthritis II-15

Disease Overview II-15

Low Penetration to Sustain growth of Anti-TNF Drugs II-15

Incidence and Prevalence Higher in Urban and Developed Regions II-15

Diagnosis II-16

Treatment of Rheumatoid Arthritis II-16

BRMs Revolutionize RA Treatment II-16

Drugs Used in Treating Rheumatoid Arthritis II-17

Table 2: Leading Biologic Drugs for Rheumatoid Arthritis

Worldwide (2007): Value Sales for Enbrel, Remicade, Humira,

Orencia, Rituxan and Kineret (US$ Million) II-17

Year of Approval of Leading Biologics in Rheumatoid

Arthritis Therapy II-18

Key Drugs In Late Stage Development for Rheumatoid Arthritis

Treatment II-18

Competitive Landscape II-18

Table 3: Comparative Analysis of Leading Biologic Rheumatoid

Arthritis Drugs based on ACR Scores by End Point II-19

High Prices and Safety Concerns II-19

Multiple Sclerosis II-20

Etiology II-20

Types of Multiple Sclerosis II-20

Table 4: Prevalence of Different Types of Multiple Sclerosis II-21

Pathology II-21

Prevalence of Multiple Sclerosis High in Women II-22

Facts About Multiple Sclerosis II-22

Treatment II-22

Interferon Drugs – High Efficacy Drugs in Existing MS Therapies II-23

Beta Interferon Drugs in Multiple Sclerosis Treatment II-23

Non-Interferon Drugs II-23

Non-Interferon Drugs in Multiple Sclerosis Treatment II-24

Trends in Multiple Sclerosis Market II-24

High Unmet Need and Rich Pipeline to Expand MS Market II-24

Interferon-based Drugs Lead Multiple Sclerosis Drug Market II-24

Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies II-25

Dip in Sales Inevitable for Current Therapies II-26

Tough Times Ahead for Betaseron II-26

Competitive Landscape II-27

Table 5: Leading Multiple Sclerosis Drugs Worldwide (2007)

by Sales: Avonex, Rebif, Copaxone, Betaseron and Tysabri

(includes corresponding Graph/Chart) II-28

Table 6: Leading Multiple Sclerosis Drugs Worldwide (2000,

2003 and 2006): Market Shares for Avonex, Rebif, Copaxone,

Betaseron and Tysabri (includes corresponding Graph/Chart) II-28

Multiple Sclerosis Drug Pipeline – An Overview II-29

Drugs Under Development for Treating Multiple Sclerosis II-29

FTY 720 (Fingolimod) II-29

Mylinax II-29

Laquinimod II-30

Campath (Alemtuzumab) – Trials Marred with Side Effects II-30

Teriflunomide II-31

Fampridine-SR II-31

BG-12 (Oral Fumarate) II-31

MN-166 II-31

Psoriasis II-32

Prevalence II-32

Available Treatment Options II-32

Biological Drugs Lead the Fray II-33

Table 7: Leading Psoriasis Drugs Worldwide (2005): Market

Share by Value Sales for Biologics (Enbrel, Raptiva and

Amevive), Systemic Drugs, and Topicals (includes

corresponding Graph/Chart) II-33

Inflammatory Bowel Diseases II-34

Crohn’s disease II-34

Stages of the Disease II-34

Prevalence II-34

Diagnosis II-34

Treatment II-35

Global Crohn’s Disease Therapeutics Market: Leading

Biological Drugs and their Worldwide II-36

Year of Approval for Leading Drugs in Crohn’s Disease

Treatment II-36

Ulcerative Colitis II-36

Diagnosis and Treatment II-36

Other Diseases II-37

Systemic Lupus Erythematosus (SLE) II-37

Prevalence and Epidemiology II-37

Treatment II-37

Sjogren’s Syndrome II-38

Prevalence and Epidemiology II-39

Diagnosis and Treatment II-39

Type-1 Diabetes Mellitus II-39

Types of Diabetes Mellitus II-40

Type 1 or Insulin Dependent Diabetes Mellitus II-40

Type 2 or Non-Insulin Dependent Diabetes Mellitus II-40

Insulin – Vital for Blood Glucose Management II-40

Etiology II-40

Prevalence II-41

Diabetes in Children – A Growing Concern II-41

Diagnosis and Treatment II-41

Autoimmune Hepatitis II-42

Disease Categories II-42

Treatment II-42

Side Effects II-42

Juvenile Rheumatoid Arthritis II-43

Symptoms II-43

Diagnosis II-43

Scleroderma II-43

Prevalence II-44

Etiology II-44

Diagnosis II-44

Management II-44

Vasculitis Syndeomes II-44

Haematologic Autoimmune Diseases II-45

Ankylosing Spondylitis II-45

5. PRODUCT INTRODUCTIONS/APPROVALS II-46

Cimzia(R) Receives FDA Approval for Treating Rheumatoid Arthritis II-46

Simponi(TM) Receives FDA Approval for Treating Rheumatoid Arthritis II-46

HUMIRA(R) Obtains EU Approval for Polyarticular Juvenile

Idiopathic Arthritis II-46

Cimzia(R) Receives FDA Nod for Treating Crohn’s Disease II-47

HUMIRA(R) Obtains Approval from Japanese Ministry for Rheumatoid

Arthritis II-47

HUMIRA(R) Receives FDA Clearance for Polyarticular Juvenile

Idiopathic Arthritis II-47

Abbott Receives EU Marketing Authorization for Humira in

Psoriasis Treatment II-47

Xian-Janssen Introduces Remicade, Branded infliximab in China II-48

HUMIRA(R) Obtains EU Approval for Treating Crohn’s Disease II-48

HUMIRA(R) Obtains FDA Approval for Crohn’s Disease II-48

Remicade(R) Obtains Approval for Use in PsA and Early RA in

Australia II-48

Tysabri(TM) Receives Health Canada Approval for Use in Multiple

Sclerosis II-49

Rituxan(R) Gets FDA Approval for Use in RA II-49

Humira(R) Obtains FDA Approval for Treating AS II-49

Betaseron(R) Receives FDA Approval for Use in First Clinical

Episode of MS II-50

Abbott Receives FDA Clearance for HUMIRA Pen II-50

Remicade Obtains FDA Approval for Treating Pediatric Crohn`s

Disease II-50

6. RECENT INDUSTRY ACTIVITY II-52

Novo Nordisk and VLST Collaborate on Therapeutic Targets

Development II-52

Actemra’s Approval Gets Delayed II-52

Apitope Raises Financing for Developing Multiple Sclerosis

Compound II-53

CalciMedica to Acquire Rights to STIM1 from TorreyPines II-53

Roche Acquires ARIUS Research, Inc. II-54

Astellas Inks Agreement with Maxygen for MAXY-4 Candidates II-54

Carna and Caliper Life Sciences Ink Collaborative Supply

Agreement II-55

Isotechnika Gets Back Worldwide Rights to Transplant Drug,

Voclosporin II-55

Boehringer In-licenses Two Drug Targets from BioFocus II-56

Bionomics Enters into a Development and Licensing Agreement

with Merck Serono II-56

Nycomed Inks Agreement with Immunomedics for Veltuzumab II-57

EpiVax Receives Grants from National Institutes of Health to

Advance Epi-13 II-57

Boehringer to Takeover Actimis II-58

Antisoma Acquires Xanthus Pharmaceuticals II-58

Merrimack Acquires Funds for Developing Cancer and Autoimmune

Disease Biologics II-59

BioSeek and Merck Sign Collaboration Agreement for Compound

Evaluation II-59

Questcor Amends Distribution Contract with US Distributor of

Acthar II-59

ANP Completes Phase Iia Trial for Multiple Sclerosis Drug II-60

Insert and Calando Merge to Form Calando Pharmaceuticals II-60

Codon Inks Research & Development and Licensing Deal with

Merrimack II-60

Debiopharm Inks licensing Deal with Airmid for Debio 0824 ShK

Peptide II-61

Chelsea Acquires Global Rights to I-3D Range of DHODH

Inhibiting Compounds II-61

Cypress Bioscience Acquires Proprius II-62

J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals II-62

GlaxoSmithKline Acquires License to Market Vaccinex’s Antibody II-62

Teva to Takeover CoGenesys II-62

Hadasit, HMS and BWH to Co-develop Oral Therapy for Autoimmune

Diseases II-63

Anthera Acquires Rights to Develop and Market AMG 623 from Amgen II-63

Can-Fite Enters into Two Cooperation Agreements to Develop

CF102 Drug II-63

Source MDx Inks an Agreement with Pfizer II-63

Cambridge Inks an Antibody Development Agreement with Medarex II-64

Pfizer to Acquire Coley Pharma II-64

GSK Joins Hands with Tolerx to Develop and Commercialize

otelixizumab II-64

Amgen Acquires Avidia II-65

Eli Lilly and MacroGenics Tie Up for Developing Teplizumab II-66

MorphoSys and Genesis Ink Antibody R&D Deal II-66

arGentis Enters into a License Agreement with UTRF II-67

Eden Biodesign to Investigate Novel Drug Candidate for

Autoimmune Diseases II-67

Nuon and Kissei Team up for Tranilast II-67

Organon and Dyax Team Up for Developing Therapeutic Antibodies II-68

Medarex Joins Hands with Mitsubishi for Monoclonal Antibody

Development II-68

Merck and Archemix Collaborate II-68

Genzyme Takes Over Bioenvision II-69

Organon and Medarex Ink Drug Development Deal II-69

CalciMedica Secures Exclusive Rights for CBR’s Autoimmune Drug

Target II-69

Xanthus Secures Exclusive Patent Estate Rights for FLT3 Pathway II-70

Eisai Corporation Acquires Morphotek II-70

TIRC Changes Name to Orchestra Therapeutics II-71

Abbott Files HUMIRA(R) for Psoriasis in the US and EU (USA/Europe) II-71

Accentia Secures Exclusive Global Rights to Revimmune II-71

Medarex and Compugen Ink Collaborative Agreement for

Therapeutic Antibody II-72

SRI and Telik Sign License Agreement for Drug Development II-73

China Biopharma Signs Agreement with Chinese Biopharmaceutical

Firm II-73

Kirin and Astellas Ink Licensing Agreement for Anti-CD40

Antagonistic mAb II-74

QSV and Artielle Sign Contract to Produce RTL-1000 II-74

JDRF and MacroGenics Form Partnership II-75

GSK and Genmad Sign Partnership Agreement for HuMaxCD20 II-75

Biocon Enters into Joint Venture Agreement with Neopharma II-76

Pipex Pharmaceuticals Acquires Remaining Stake in Effective

Pharmaceuticals II-76

Astellas Acquires Worldwide Rights for Amevive(R) II-77

Biogen Acquires Fumapharm II-77

Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy II-77

7. FOCUS ON SELECT GLOBAL PLAYERS II-78

Abbott Laboratories (USA) II-78

Amgen Inc. (USA) II-78

Bayer Schering Pharma AG (Germany) II-79

Biogen Idec Inc. (USA) II-80

Bristol-Myers Squibb Company (USA) II-81

Elan Corporation, plc (Ireland) II-82

Eli Lilly And Company (USA) II-83

F. Hoffmann-La Roche AG (Switzerland) II-83

Chugai Pharmaceutical Co., Ltd. (Japan) II-84

Genentech, Inc. (USA) II-85

GlaxoSmithKline plc (UK) II-86

Johnson & Johnson, Inc. (USA) II-87

Merck Serono SA (Switzerland) II-88

Novartis AG (Switzerland) II-88

Sanofi-aventis SA (France) II-89

Schering-Plough Corporation (USA) II-90

Shire Pharmaceuticals Group plc (Ireland) II-90

Teva Pharmaceuticals Industries Limited (Israel) II-91

UCB Pharma (Belgium) II-92

8. GLOBAL MARKET PERSPECTIVE II-93

Table 8: World Recent Past, Current & Future Analysis for

Autoimmune Disease Therapeutics by Geographic Region – US,

Japan, Europe and Rest of World Markets Independently Analyzed

with Annual Sales in US$ Billion for Years 2006 through 2015

(includes corresponding Graph/Chart) II-93

Table 9: World 10-year Perspective for Autoimmune Disease

Therapeutics by Geographic Region – Percentage Breakdown of

Dollar Sales for US, Japan, Europe and Rest of World Markets

for Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-94

Table 10: World Recent Past, Current & Future Analysis for

Rheumatoid Arthritis Therapeutics by Geographic Region – US,

Japan, Europe and Rest of World Markets Independently Analyzed

with Annual Sales in US$ Billion for Years 2006 through 2015

(includes corresponding Graph/Chart) II-95

Table 11: World 10-year Perspective for Rheumatoid Arthritis

Therapeutics by Geographic Region – Percentage Breakdown of

Dollar Sales for US, Japan, Europe and Rest of World Markets

for Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-96

Table 12: World Recent Past, Current & Future Analysis for

Multiple Sclerosis Therapeutics by Geographic Region – US,

Japan, Europe and Rest of World- Markets Independently

Analyzed with Annual Sales in US$ Billion for Years 2006

through 2015 (includes corresponding Graph/Chart) II-97

Table 13: World 10-year Perspective for Multiple Sclerosis

Therapeutics by Geographic Region – Percentage Breakdown of

Dollar Sales for US, Japan, Europe and Rest of World Markets

for Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-98

Table 14: World Recent Past, Current & Future Analysis for

Psoriasis Therapeutics by Geographic Region – US, Japan,

Europe and Rest of World- Markets Independently Analyzed with

Annual Sales in US$ Billion for Years 2006 through 2015

(includes corresponding Graph/Chart) II-99

Table 15: World 10-year Perspective for Psoriasis Therapeutics

by Geographic Region – Percentage Breakdown of Dollar Sales

for US, Japan, Europe and Rest of World Markets for Years

2006, 2009 & 2015 (includes corresponding Graph/Chart) II-100

Table 16: World Recent Past, Current & Future Analysis for

Crohn’s Disease Therapeutics (Biologics) by Geographic Region

- US, Japan, Europe and Rest of World- Markets Independently

Analyzed with Annual Sales in US$ Billion for Years 2006

through 2015 (includes corresponding Graph/Chart) II-101

Table 17: World 10-year Perspective for Crohn’s Disease

Therapeutics (Biologics) by Geographic Region – Percentage

Breakdown of Dollar Sales for US, Japan, Europe and Rest of

World Markets for Years 2006, 2009 & 2015 (includes

corresponding Graph/Chart) II-102

Table 18: World Recent Past, Current & Future Analysis for

Other Autoimmune Disease Therapeutics by Geographic Region -

US, Japan, Europe and Rest of World- Markets Independently

Analyzed with Annual Sales in US$ Billion for Years 2006

through 2015 (includes corresponding Graph/Chart) II-103

Table 19: World 10-year Perspective for Other Autoimmune

Disease Therapeutics by Geographic Region – Percentage

Breakdown of Dollar Sales for US, Japan, Europe and Rest of

World Markets for Years 2006, 2009 & 2015 (includes

corresponding Graph/Chart) II-104

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Current and Future Analysis III-1

Autoimmune Diseases Fact Sheet III-1

Table 20: Prevalence of Key Autoimmune Diseases in the US

for 2006 (in Millions) (includes corresponding Graph/Chart) III-2

Market Trends III-2

Biologic Drugs Lead the Fray III-2

Biologics To Add Further Impetus to the Market III-2

Rheumatoid Arthritis Drugs Lead the Market III-3

Enbrel and Humira Continue to Gain Share in the Anti-TNF

Market III-3

Increased Incidence and Rise in Drug Prices to Drive Growth

in MS Market III-3

Table 21: US Multiple Sclerosis Drug Market (2006):

Percentage Breakdown of Number of Dispensed Prescriptions

for Avonex, Copaxone, Rebif, Betaseron and Tysabri

(includes corresponding Graph/Chart) III-4

Incidence of Type 1 Diabetes Mellitus Endemic in White Youth III-4

Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs

Market III-4

Key Ulcerative Colitis Drugs Market in the US (2006) III-5

Table 22: US Ulcerative Colitis Drugs Market (2007 &

2008): Percentage Breakdown of Prescriptions Dispensed

Ranked by Leading Drugs for Asacol, Pentasa, Lialda,

Canasa, Sulphasalazine, Colazal, Other Drugs and Generics

(includes corresponding Graph/Chart) III-5

Product Launches/ Approvals III-6

Strategic Corporate Developments III-9

Key Players III-28

B.Market Analytics III-36

Table 23: US Recent Past, Current & Future Analysis for

Autoimmune Disease Therapeutics by Disease Segment -

Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn’s

Disease (Biologics) and Other Autoimmune Diseases

Independently Analyzed with Annual Sales in US$ Billion for

Years 2006 through 2015 (includes corresponding Graph/Chart) III-36

Table 24: US 10-year Perspective for Autoimmune Disease

Therapeutics by Disease Segment – Percentage Breakdown of

Dollar Sales for Rheumatoid Arthritis, Multiple Sclerosis,

Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune

Diseases for Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) III-37

2. JAPAN III-38

A.Market Analysis III-38

Current and Future Analysis III-38

Product Launches/Approvals III-38

Key Players III-38

B.Market Analytics III-39

Table 25: Japanese Recent Past, Current & Future Analysis

for Autoimmune Disease Therapeutics by Disease Segment -

Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn’s

Disease (Biologics) and Other Autoimmune Diseases

Independently Analyzed with Annual Sales in US$ Billion for

Years 2006 through 2015 (includes corresponding

Graph/Chart) III-39

Table 26: Japanese 10-year Perspective for Autoimmune

Disease Therapeutics by Disease Segment – Percentage

Breakdown of Dollar Sales for Rheumatoid Arthritis, Multiple

Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other

Autoimmune Diseases for Years 2006, 2009 & 2015 (includes

corresponding Graph/Chart) III-40

3. EUROPE III-41

A.Market Analysis III-41

Current and Future Analysis III-41

Europe – A Burgeoning Market for Autoimmune Disease

Therapeutics III-41

Increasing Awareness to Drive Market Growth III-41

Low Penetration to Fuel Growth in European MS DMDs Market III-41

Table 27: Prevalence of Key Autoimmune Diseases in Europe

for 2006 in Millions (includes corresponding Graph/Chart) III-42

Lower Treatment Rate Bodes Huge Potential for the UK MS

Drug Market III-42

Drugs Hindering Disease Progression to Gain Prominence III-42

Product Launches/Approvals III-43

Strategic Corporate Developments III-44

Key Players III-47

B.Market Analytics III-55

Table 28: European Recent Past, Current & Future Analysis

for Autoimmune Disease Therapeutics by Disease Segment -

Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn’s

Disease (Biologics) and Other Autoimmune Diseases

Independently Analyzed with Annual Sales in US$ Billion for

Years 2006 through 2015 (includes corresponding Graph/Chart) III-55

Table 29: European 10-year Perspective for Autoimmune

Disease Therapeutics by Disease Segment – Percentage

Breakdown of Dollar Sales for Rheumatoid Arthritis, Multiple

Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other

Autoimmune Diseases for Years 2006, 2009 & 2015 (includes

corresponding Graph/Chart) III-56

4. REST OF WORLD III-57

A.Market Analysis III-57

Current and Future Analysis III-57

Canada III-57

Canada – Highest Prevalence Rates for Multiple Sclerosis III-57

Sales of Biologics on the Rise in Canadian Rheumatoid

Arthritis Drugs Market III-57

Asia-Pacific III-58

Autoimmune Diseases Market in Asia-Pacific – An Overview III-58

Incidence of Multiple Sclerosis in India on the Rise III-58

Overview of Rheumatoid Arthritis in Australia III-59

Table 30: Percentage Breakdown of Prevalence of

Rheumatoid Arthritis in Australia by Age Group (includes

corresponding Graph/Chart) III-59

Table 31: Percentage Breakdown of Prevalence of

Rheumatoid Arthritis in Australia by Sex (includes

corresponding Graph/Chart) III-60

Overview of Irritable Bowel Diseases in Australia III-60

Product Launches/Approvals III-61

Strategic Corporate Developments III-62

B.Market Analytics III-65

Table 32: Rest of World Recent Past, Current & Future

Analysis for Autoimmune Disease Therapeutics by Disease

Segment – Rheumatoid Arthritis, Multiple Sclerosis,

Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune

Diseases Independently Analyzed with Annual Sales in US$

Billion for Years 2006 through 2015 (includes corresponding

Graph/Chart) III-65

Table 33: Rest of World 10-year Perspective for Autoimmune

Disease Therapeutics by Disease Segment – Percentage

Breakdown of Dollar Sales for Rheumatoid Arthritis, Multiple

Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other

Autoimmune Diseases for Years 2006, 2009 & 2015 (includes

corresponding Graph/Chart) III-66

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 115 (including Divisions/Subsidiaries – 122)

To order this report:

Autoimmune Disease Therapeutics

http://www.reportlinker.com/p0131243/Autoimmune-Disease-Therapeutics.html

More market research reports here!

    Contact:
    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus